Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.
J Am Heart Assoc · 2025-Nov-04 · PMID 41128134
Net clinical benefit
Figure 2. Net clinical benefit of the VOYAGER PAD efficacy and safety outcomes. Outcomes using various combined efficacy and safety end points at 3 years, comparing rivaroxaban to placebo. All analyses included myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation. A , Included cardiovascular death and intracranial or fatal bleeding. B , Included cardiovascular death and TIMI major bleeding. C , Included all‐cause death and intracranial or fatal bleeding. D , Included all‐cause death and TIMI major bleeding. ASA indicates acetylsalicylic acid (aspirin); TIMI indicates thrombolysis in myocardial infarction; and VOYAGER PAD, Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T17:58:40+00:00 |